Aminophylline: pharmacological effects, clinical applications and manufacturer overview

Aminophylline is a drug widely used in respiratory diseases. Its main component is a complex of theophylline and ethylenediamine. It hasbronchiectasisandanti-inflammatory effect. This article will focus on its pharmacological mechanism, indications, usage and dosage, adverse reactions and manufacturers, focusing on analyzing its core position in the treatment of asthma and chronic obstructive pulmonary disease (COPD), along with authoritative data and product information.

Pharmacological effects and indications

Aminophylline increases intracellular cyclic adenosine monophosphate (cAMP) levels by inhibiting phosphodiesterase, thereby relaxing bronchial smooth muscle and improving ventilatory function. Mainly used clinicallybronchial asthma,acute exacerbation of COPDand adjuvant treatment of cardiac asthma. Its sustained-release preparation can maintain stable blood drug concentration and reduce the frequency of medication. It should be noted that the therapeutic window is narrow and plasma concentrations need to be monitored to avoid toxic reactions.

Usage, dosage and precautions

The usual oral dosage for adults is 0.1-0.2g/time, 3 times a day; intravenous injection requires slow infusion to avoid arrhythmia. Elderly patients and those with liver insufficiency need to reduce the dose. Common adverse reactions includePalpitations,Disgusting, which may cause convulsions in severe cases. Combination with quinolone antibiotics may increase theophylline blood concentration, and the dose needs to be adjusted.

Manufacturer and product information

Summary and safety tips

Aminophylline, as a classic antiasthmatic drug, is effective but needs to be used in a standardized manner. Patients should follow medical advice and avoid taking it with caffeine to aggravate the central stimulant effect. At present, the products of domestic mainstream manufacturers have passed consistency evaluation and are of reliable quality. Quoted from the "Chinese Pharmacopoeia" (2020 edition) and the "Guidelines for the Prevention and Treatment of Bronchial Asthma" of the Respiratory Disease Branch of the Chinese Medical Association.